CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires Agilux Laboratories
Snapshot
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Agilux Laboratories for $64.9 million in cash in September 2016. The transaction was structured as all cash. Agilux Laboratories is a United States-based Discovery and Safety Assessment (DSA) business.
- Acquirer
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Target
- Agilux Laboratories
- Value
- $64.9 million in cash
- Date
- September 2016
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Agilux Laboratories for $64.9 million in cash, a transaction completed in September 2016, structured as all cash.
Agilux Laboratories operates in Discovery and Safety Assessment (DSA), is based in United States. Agilux was a CRO that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services, and pharmacology services.
The acquisition supports our strategy to offer clients a broader, integrated portfolio that provides services continuously from the earliest stages of drug research through the nonclinical development process. The purchase price for Agilux was $64.9 million in cash.
DSA segment, discovery / DMPK services
No advisory firms have been disclosed for this transaction.